Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report) shares passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $3.74 and traded as low as $3.49. Prime Medicine shares last traded at $3.55, with a volume of 6,127,062 shares traded.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on PRME shares. Weiss Ratings restated a “sell (e+)” rating on shares of Prime Medicine in a research note on Monday, August 31st. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Prime Medicine in a research report on Monday, November 16th. Wall Street Zen upgraded Prime Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. BMO Capital Markets assumed coverage on Prime Medicine in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $9.00 target price on the stock. Finally, Citigroup reiterated a “market outperform” rating on shares of Prime Medicine in a research note on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.86.
Read Our Latest Analysis on Prime Medicine
Prime Medicine Trading Down 7.6%
The firm has a 50-day moving average of $3.74 and a 200 day moving average of $3.51. The stock has a market capitalization of $645.82 million, a price-to-earnings ratio of -3.70 and a beta of 2.14.
Prime Medicine (NASDAQ:PRME – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. The business had revenue of $4.21 million for the quarter. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 286.97%. Equities research analysts predict that Prime Medicine, Inc. will post -0.94 EPS for the current fiscal year.
Institutional Trading of Prime Medicine
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Alphabet Inc. bought a new stake in Prime Medicine during the second quarter worth approximately $61,116,000. BlackRock Inc. acquired a new stake in shares of Prime Medicine during the 2nd quarter valued at $35,432,000. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Prime Medicine by 20.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,911,596 shares of the company’s stock valued at $8,895,000 after acquiring an additional 498,612 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Prime Medicine during the 2nd quarter valued at $7,371,000. Finally, Redmile Group LLC bought a new stake in shares of Prime Medicine during the 1st quarter worth $5,536,000. 70.37% of the stock is currently owned by institutional investors.
About Prime Medicine
Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.
Further Reading
- Five stocks we like better than Prime Medicine
- Growing Pains Versus Growth: Is BJ’s Wholesale Club a Buying Opportunity?
- Keysight Technologies: The Tollbooth on the Technology Superhighway
- Zscaler Got a Boost From Palo Alto, But Now It Has to Deliver.
- Bargain Hunting: Why Off-Price Retail Is Winning
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
